The company signed the agreement on the investment

2021-12-02

On December 2nd, Hu Jian, general manager of the company, and Wu Mingming, general manager of Shanghai Yujun Biotechnology Development Co., Ltd. signed the investment agreement, marking the strategic cooperation between the two sides. This cooperation will help both sides give full play to the advantages of their respective platforms and carry out in-depth cooperation in multiple business areas.

Shanghai Yujun Biotechnology Development Co., Ltd. is a CRO/CDMO company serving the field of innovative drugs and new materials, focusing on technology accumulation and breakthrough of main products for a long time. Yujun bio's current R&D center is located in Minhang, Shanghai, with a new 3,600-square-meter first phase and a 6,700-square-meter second phase in Lingang, Shanghai. The first phase is expected to be put into operation in early 2022, with additional r&d centers in Xi 'an and Wuhan in preparation. Yujun biological is good at many special technologies, such as alkylation technology, ultra-low temperature reaction, ozone reaction, etc., and also good at new continuous flow reaction forms, and has rich experience in the application of metal catalysis and enzyme catalysis technology, has strong competitiveness in the industry.

The contrast agent preparation products are on the market and entered the national collective procurement, marking the landing of the integrated strategy of "intermediate-raw material-preparation" of our company, which is more mature and stable in the development of the subdivision of contrast agent. The opening of this cooperation also marks our company's development and exploration in the new business section, injecting fresh vitality into the sustainable development of the company's business.